NBRLBoston
NBRLBoston is dedicated to developing novel anti-cancer and infectious diseases immune therapies, including tumor immune therapy, cell and gene drug R&D, and intrabody development. The company originated from E&E Bio-Research Lab and has expanded its focus to anti-tumor immune gene drugs, intrabody candidates, and advanced immunotherapy platforms. It aims to support health through innovative biological therapeutics targeting cancer, Alzheimer's disease, and viral infections.
Industries
Nr. of Employees
small (1-50)
NBRLBoston
299a Washington Street, Woburn, Massachusetts 01801, United States
Products
Intrabody gene drug candidates
Gene-delivered intracellular antibody constructs intended to target cytosolic disease-associated proteins for cancer, viral infections, and other intracellular targets.
mRNA/DNA anti-tumor gene therapeutic combos with T and NK cells
mRNA/DNA-based gene therapeutics intended to modulate tumor immunity, developed for combination use with peripheral blood or iPSC-derived T and NK cell products.
Bispecific and multi‑specific antibody and Fc‑fusion protein candidates (incl. anti‑Aβ/AD candidates)
Bispecific and multispecific antibody formats and Fc-fusion proteins targeting multiple disease-associated epitopes, including candidates aimed at amyloid‑β, tau, and α‑synuclein for neurodegenerative disease.
iPSC/stem cell-based therapeutics for Alzheimer’s disease
Development of stem cell or iPSC-derived cell therapy approaches targeting neurodegeneration associated with Alzheimer's disease.
Universal iPSC-derived NK and T cell candidates; CAR/TCRm NK products
Development-stage universal, off-the-shelf iPSC-derived NK and T cells and engineered NK cells expressing CAR or TCR-mimic receptors for cancer immunotherapy.
Intrabody gene drug candidates
Gene-delivered intracellular antibody constructs intended to target cytosolic disease-associated proteins for cancer, viral infections, and other intracellular targets.
mRNA/DNA anti-tumor gene therapeutic combos with T and NK cells
mRNA/DNA-based gene therapeutics intended to modulate tumor immunity, developed for combination use with peripheral blood or iPSC-derived T and NK cell products.
Bispecific and multi‑specific antibody and Fc‑fusion protein candidates (incl. anti‑Aβ/AD candidates)
Bispecific and multispecific antibody formats and Fc-fusion proteins targeting multiple disease-associated epitopes, including candidates aimed at amyloid‑β, tau, and α‑synuclein for neurodegenerative disease.
iPSC/stem cell-based therapeutics for Alzheimer’s disease
Development of stem cell or iPSC-derived cell therapy approaches targeting neurodegeneration associated with Alzheimer's disease.
Universal iPSC-derived NK and T cell candidates; CAR/TCRm NK products
Development-stage universal, off-the-shelf iPSC-derived NK and T cells and engineered NK cells expressing CAR or TCR-mimic receptors for cancer immunotherapy.
Services
Discovery of single-domain nanobodies and engineering of bi-/multi-specific antibodies and masked (pro-) antibody constructs for improved selectivity.
Development and optimization of non-viral gene delivery, nanoparticle formulations, receptor-mediated endocytosis targeting, and CPP conjugation methods to enable intracellular antibody therapeutics.
In vitro and in vivo efficacy testing, ex vivo evaluation with patient tissue/CSF, MOA characterization, PK/PD, toxicity assessments, and preparation for CMC/GMP and IND filings.
Development of iPSC- or stem cell–derived universal NK and T cell products and engineered NK cells expressing CAR or TCR‑mimic receptors for cancer immunotherapy.
Discovery of single-domain nanobodies and engineering of bi-/multi-specific antibodies and masked (pro-) antibody constructs for improved selectivity.
Development and optimization of non-viral gene delivery, nanoparticle formulations, receptor-mediated endocytosis targeting, and CPP conjugation methods to enable intracellular antibody therapeutics.
In vitro and in vivo efficacy testing, ex vivo evaluation with patient tissue/CSF, MOA characterization, PK/PD, toxicity assessments, and preparation for CMC/GMP and IND filings.
Development of iPSC- or stem cell–derived universal NK and T cell products and engineered NK cells expressing CAR or TCR‑mimic receptors for cancer immunotherapy.
Expertise Areas
- Intrabody and intracellular biologic delivery
- Antibody discovery and engineering (including bispecific and multispecific formats)
- mRNA/DNA therapeutic design for immune modulation
- Cell therapy development (iPSC-derived NK/T and universal cell products)
Key Technologies
- Non-viral gene delivery
- Nanoparticle and liposomal formulations
- Receptor-mediated endocytosis targeting
- Cell-penetrating peptides (CPP) conjugation